IART Q3 2024 Earnings — Integra LifeSciences Holdings Corporation Revenue & Financial Results | Market Cap Arena

IARTIntegra LifeSciences Holdings Corporation

$738M

Q3 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$381M-0.4% YoY

Gross Profit

$200M52.6% margin

Operating Income

-$8M-2.1% margin

Net Income

-$11M-2.8% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

-8.9%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

-$7M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$4.1B

Total Liabilities

$2.5B

Stockholders' Equity

$1.5B

Cash & Equivalents

$215M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$381M	$382M	-0.4%
Gross Profit	$200M	$218M	-8.3%
Operating Income	-$8M	$27M	-130.6%
Net Income	-$11M	$19M	-154.9%

Revenue Segments

Codman Specialty Surgical

$271M71%

Tissue Technologies

$110M29%

Geographic Segments

UNITED STATES

$290M76%

Asia Pacific

$37M10%

Europe

$34M9%

Rest Of World

$19M5%